Literature DB >> 30609005

Analysis of the Frequency and Mechanism of Injury to Warfighters in the Under-body Blast Environment.

Kerry Danelson1, Laura Watkins1, Jonathan Hendricks1, Patricia Frounfelker2, Karen Pizzolato-Heine2, Ray Valentine2, Kathryn Loftis2.   

Abstract

During Operation Iraqi Freedom and Operation Enduring Freedom, improvised explosive devices were used strategically and with increasing frequency. To effectively design countermeasures for this environment, the Department of Defense identified the need for an under-body blast-specific Warrior Injury Assessment Manikin (WIAMan). To help with this design, information on Warfighter injuries in mounted under-body blast attacks was obtained from the Joint Trauma Analysis and Prevention of Injury in Combat program through their Request for Information interface. The events selected were evaluated by Department of the Army personnel to confirm they were representative of the loading environment expected for the WIAMan. A military case review was conducted for all AIS 2+ fractures with supporting radiology. In Warfighters whose injuries were reviewed, 79% had a foot, ankle or leg AIS 2+ fracture. Distal tibia, distal fibula, and calcaneus fractures were the most prevalent. The most common injury mechanisms were bending with probable vehicle contact (leg) and compression (foot). The most severe injuries sustained by Warfighters were to the pelvis, lumbar spine, and thoracic spine. These injuries were attributed to a compressive load from the seat pan that directly loaded the pelvis or created flexion in the lumbar spine. Rare types of injuries included severe abdominal organ injury, severe brain injury, and cervical spine injury. These typically occurred in conjunction with other fractures. Mitigating the frequently observed skeletal injuries using the WIAMan would have substantial long-term benefits for Warfighters.

Entities:  

Mesh:

Year:  2018        PMID: 30609005     DOI: 10.4271/2018-22-0014

Source DB:  PubMed          Journal:  Stapp Car Crash J        ISSN: 1532-8546


  7 in total

1.  Verification of High-Rate Vertical Loading Laboratory Skeletal Fractures by Comparison with Theater Injury Patterns.

Authors:  K A Danelson; J G Polich; D R Barnes; G S Bullock; A T Scott; J J Halvorson; T O'Gara; H T Pilson; S Babcock; J Birkedal; B McAllister; K L Loftis
Journal:  Ann Biomed Eng       Date:  2021-10-15       Impact factor: 3.934

2.  Human Pelvis Bayesian Injury Probability Curves From Whole Body Lateral Impact Experiments.

Authors:  Narayan Yoganandan; Nicholas DeVogel; Frank Pintar; Anjishnu Banerjee
Journal:  J Eng Sci Med Diagn Ther       Date:  2020-04-16

3.  Human Thoracolumbar Spine Tolerance to Injury and Mechanisms From Caudo-Cephalad Loading: A Parametric Modeling Study.

Authors:  Narayan Yoganandan; Prashant Khandelwal; Vaibhav Porwal; John Humm; Anjishnu Banerjee
Journal:  J Eng Sci Med Diagn Ther       Date:  2021-02-01

4.  Lower Extremity Impact and Injury Responses of Male and Female PMHS to High-Rate Vertical Loading.

Authors:  D Cristino; H Pietsch; A Kemper; J Bolte; K Danelson; W Hardy
Journal:  Ann Biomed Eng       Date:  2021-07-26       Impact factor: 3.934

5.  Methodology for Evaluation of WIAMan Injury Assessment Reference Curves Using Whole Body Match-Paired Data.

Authors:  David R Barnes; Kerry A Danelson; Nitin M Moholkar; Kathryn L Loftis
Journal:  Ann Biomed Eng       Date:  2021-04-20       Impact factor: 3.934

6.  Severe Calcaneus Injury Probability Curves Due to Under-Body Blast.

Authors:  Liming Voo; Kyle Ott; Thomas Metzger; Andrew Merkle; David Drewry
Journal:  Ann Biomed Eng       Date:  2021-06-11       Impact factor: 3.934

7.  Dynamic Response of the Thoracolumbar and Sacral Spine to Simulated Underbody Blast Loading in Whole Body Post Mortem Human Subject Tests.

Authors:  Donald Sherman; Karthik Somasundaram; Paul Begeman; Sierra Foley; Jason Greb; Cynthia Bir; Constantine K Demetropoulos; John M Cavanaugh
Journal:  Ann Biomed Eng       Date:  2021-03-15       Impact factor: 3.934

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.